We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Elevance Health (ELV) Q1 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
The upcoming report from Elevance Health (ELV - Free Report) is expected to reveal quarterly earnings of $10.61 per share, indicating a decline of 11.4% compared to the year-ago period. Analysts forecast revenues of $48.37 billion, representing a decline of 0.8% year over year.
Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Elevance Health metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Revenues- Net investment income' at $480.23 million. The estimate suggests a change of -18.6% year over year.
Analysts' assessment points toward 'Revenues- Service fees' reaching $2.13 billion. The estimate points to a change of +3.1% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Premiums' should arrive at $40.13 billion. The estimate indicates a change of -1.8% from the prior-year quarter.
The consensus estimate for 'Revenues- Product revenue' stands at $6.09 billion. The estimate points to a change of +4.9% from the year-ago quarter.
Analysts forecast 'Total Medical Membership' to reach 44.05 million. The estimate compares to the year-ago value of 45.83 million.
It is projected by analysts that the 'Medical Membership - Medicare - Medicare Advantage' will reach 1.84 million. Compared to the present estimate, the company reported 2.26 million in the same quarter last year.
The combined assessment of analysts suggests that 'Medical Membership - Medicaid' will likely reach 8.11 million. Compared to the present estimate, the company reported 8.86 million in the same quarter last year.
The consensus among analysts is that 'Medical Membership - Federal Employees Health Benefits' will reach 1.59 million. Compared to the current estimate, the company reported 1.65 million in the same quarter of the previous year.
Analysts predict that the 'Medical Membership - Total Medicare' will reach 2.69 million. The estimate compares to the year-ago value of 3.13 million.
According to the collective judgment of analysts, 'Medical Membership - Commercial Risk-Based - Individual' should come in at 1.06 million. The estimate is in contrast to the year-ago figure of 1.42 million.
Analysts expect 'Benefit Expense Ratio' to come in at 87.5%. The estimate is in contrast to the year-ago figure of 86.4%.
The collective assessment of analysts points to an estimated 'Medical Membership - Commercial Fee-Based' of 27.29 million. Compared to the present estimate, the company reported 27.13 million in the same quarter last year.
Over the past month, shares of Elevance Health have returned +8.5% versus the Zacks S&P 500 composite's +5.2% change. Currently, ELV carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Stay Ahead of the Game With Elevance Health (ELV) Q1 Earnings: Wall Street's Insights on Key Metrics
The upcoming report from Elevance Health (ELV - Free Report) is expected to reveal quarterly earnings of $10.61 per share, indicating a decline of 11.4% compared to the year-ago period. Analysts forecast revenues of $48.37 billion, representing a decline of 0.8% year over year.
Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Elevance Health metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Revenues- Net investment income' at $480.23 million. The estimate suggests a change of -18.6% year over year.
Analysts' assessment points toward 'Revenues- Service fees' reaching $2.13 billion. The estimate points to a change of +3.1% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Premiums' should arrive at $40.13 billion. The estimate indicates a change of -1.8% from the prior-year quarter.
The consensus estimate for 'Revenues- Product revenue' stands at $6.09 billion. The estimate points to a change of +4.9% from the year-ago quarter.
Analysts forecast 'Total Medical Membership' to reach 44.05 million. The estimate compares to the year-ago value of 45.83 million.
It is projected by analysts that the 'Medical Membership - Medicare - Medicare Advantage' will reach 1.84 million. Compared to the present estimate, the company reported 2.26 million in the same quarter last year.
The combined assessment of analysts suggests that 'Medical Membership - Medicaid' will likely reach 8.11 million. Compared to the present estimate, the company reported 8.86 million in the same quarter last year.
The consensus among analysts is that 'Medical Membership - Federal Employees Health Benefits' will reach 1.59 million. Compared to the current estimate, the company reported 1.65 million in the same quarter of the previous year.
Analysts predict that the 'Medical Membership - Total Medicare' will reach 2.69 million. The estimate compares to the year-ago value of 3.13 million.
According to the collective judgment of analysts, 'Medical Membership - Commercial Risk-Based - Individual' should come in at 1.06 million. The estimate is in contrast to the year-ago figure of 1.42 million.
Analysts expect 'Benefit Expense Ratio' to come in at 87.5%. The estimate is in contrast to the year-ago figure of 86.4%.
The collective assessment of analysts points to an estimated 'Medical Membership - Commercial Fee-Based' of 27.29 million. Compared to the present estimate, the company reported 27.13 million in the same quarter last year.
View all Key Company Metrics for Elevance Health here>>>Over the past month, shares of Elevance Health have returned +8.5% versus the Zacks S&P 500 composite's +5.2% change. Currently, ELV carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .